Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.40 |
| ▸ | GSK3B | P49841 | 3/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.38 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14973070 | 0.89 | BRAF (0.42) | GSK3BSTAT3SMPD1SPHK2 | |
| SCHEMBL14973360 | 0.89 | S1PR1 (0.46) | KCNT1HDAC1HDAC8HDAC6GRM2 | |
| SCHEMBL14973380 | 0.88 | S1PR1 (0.46) | HDAC1HDAC8HDAC6S1PR1S1PR3 | |
| SCHEMBL14973077 | 0.88 | S1PR1 (0.55) | HDAC1HDAC8HDAC6S1PR1S1PR3 | |
| SCHEMBL14973239 | 0.88 | SMPD1 (0.41) | HDAC1HDAC8HDAC6S1PR1STAT3 | |
| SCHEMBL14973025 | 0.87 | S1PR1 (0.46) | S1PR1S1PR3SMPD1 | |
| SCHEMBL14973366 | 0.87 | HDAC6 (0.47) | KCNT1HDAC1HDAC8HDAC6GRM2 | |
| SCHEMBL14973124 | 0.84 | CHUK (0.47) | S1PR1STAT3SMPD1NR1H4 | |
| SCHEMBL14973120 | 0.84 | S1PR1 (0.46) | S1PR1S1PR3SMPD1SPHK2 | |
| SCHEMBL14973268 | 0.83 | NR1H4 (0.45) | S1PR1STAT3NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2604602-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-20130137865-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-30 | — | — | US | disclosed |
| US-20130137865-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-30 | — | — | US | disclosed |
| US-20130137865-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137865-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | GRIN2C, GRIN2B, GRIN3A | KCNT1 1503/4885HDAC1 239/4885HDAC8 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.